Immunotherapy developer expands at Oxford Science Park

Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has expanded its R&D capabilities by taking new laboratory and office space in the Bellhouse Building at Oxford Science Park. The new premises, which Scancell